Use of acid suppressive therapy in hospitalized non-critically ill patients

Marwan Sheikh-Taha, Sarah Alaeddine, Julie Nassif

Marwan Sheikh-Taha, Sarah Alaeddine, Julie Nassif, Lebanese American University, Byblos 10115, Lebanon
Author contributions: All authors contributed to this paper equally.
Correspondence to: Marwan Sheikh-Taha, Associate Professor, Lebanese American University, PO Box 36, Byblos 10115, Lebanon. marwan.taha@lau.edu.lb
Telephone: +1-801-1761883 Fax: +1-801-1761883
Received: June 8, 2012 Revised: November 15, 2012
Accepted: November 20, 2012
Published online: December 6, 2012

Abstract
AIM: To assess the appropriateness of prescribing acid suppressive therapy (AST) in a general medicine service in a tertiary care hospital.

METHODS: In this retrospective observational study, we reviewed the inpatient records of all patients admitted to the general medical service in a tertiary care hospital in Beirut, Lebanon, from April 1 to May 31, 2011. Treatment with AST was considered appropriate if the patient had a specific indication or appropriate treatment purpose [e.g., gastro-esophageal reflux disease (GERD), peptic ulcer disease, dyspepsia, acute or suspected gastrointestinal (GI) bleeding]. Appropriate administration of stress ulcer prophylaxis (SUP) was derived from an internal guideline that is based on the American Society of Health System Pharmacists guidelines. Prophylaxis was considered appropriate if a patient had 1 absolute indication (coagulopathy or requiring mechanical ventilation), or 2 or more relative indications (sepsis, occult bleeding, use of high dose corticosteroids, recent use of non-steroidal anti-inflammatory drugs for more than 3 mo, renal or liver failure, enteral feeding and anticoagulant use).

RESULTS: Of the 153 patient admissions during the study period, 130 patients (85%) were started on AST, out of which 11 (8.5%) had a diagnosis that supported the use of this therapy (GI bleed, gastritis and GERD), 16 (12.3%) had an absolute indication for SUP, 59 (45.4%) had 2 or more relative indications for SUP, and 44 (33.8%) received AST without an appropriate indication. In addition, one patient with an absolute indication for SUP and four with two or more relative indications did not receive AST. Rabeprazole was the most frequently used AST (59.2%), followed by omeprazole (24.6%), esomeprazole (11.6%) and ranitidine (4.6%). The dose of AST was appropriate in 126 patients (96.9%) and the route of administration was appropriate in 123 patients (94.6%). Fifteen of the admitted patients (10%) were discharged on AST, 7 of which (47%) did not have an appropriate indication.

CONCLUSION: AST is overused in hospitalized non-critically ill patients and many patients are discharged on unnecessary AST which can increase cost, drug interactions and adverse events. Potential interventions include implementation of institutional protocols and prescriber education.

© 2012 Baishideng. All rights reserved.

Key words: Acid suppressive therapy; Stress ulcer prophylaxis; Proton pump inhibitors; Histamine-2 receptor antagonists

Peer reviewer: Omar Mohamed Abdel-Salam, Professor, Department of Toxicology and Narcotics, Medical Division, National Research Center, Tahrir Street, Dokki, Cairo 11787, Egypt
Sheikh-Taha M, Alaeddine S, Nassif J. Use of acid suppressive therapy in hospitalized non-critically ill patients. World J Gastrointest Pharmacol Ther 2012; 3(6): 93-96 Available from: URL: http://www.wjgnet.com/2150-5349/full/v3/i6/93.htm DOI: http://dx.doi.org/10.4292/wjgpt.v3.i6.93

INTRODUCTION

Acid suppressive therapy (AST), mainly proton pump
inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs), is indicated in a number of acid-related disorders, including the treatment of upper gastrointestinal (GI) bleeding, gastro-esophageal reflux disease (GERD), erosive gastritis or esophagitis, dyspepsia, reduction of GI ulcers and complications in patients taking non-steroidal anti-inflammatory drugs (NSAIDs), peptic ulcer disease (PUD) and stress ulcer prophylaxis (SUP) in high risk patients. Current evidence suggests that AST is commonly prescribed for SUP to hospitalized non-critically ill patients without an appropriate indication[1-7]. While in appropriately selected patients in the intensive care unit (ICU) prophylaxis appears to be beneficial, according to the American Society of Health System Pharmacists (ASHP), prophylaxis is not recommended or supported for medical patients who are not in an ICU[8]. Important factors noted in the ASHP guidelines include mechanical ventilation for more than 48 h and coagulopathy, or the presence of 2 or more risk factors. Reasons behind unjustified AST prescribing habits are often unclear and a large number of patients receive this form of therapy with no apparent indication. Furthermore, it appears that once AST is started, medications are continued even after discharge, resulting in unnecessary increased drug cost and adverse events[5,6]. The purpose of this study was to assess the appropriateness of prescribing AST therapy in a general medicine service in a tertiary care hospital.

MATERIALS AND METHODS

In this retrospective observational study, we reviewed the inpatient records of all patients admitted to the general medical service in a tertiary care hospital in Beirut, Lebanon, for a period of 2 mo, from April 1 till May 31, 2011. We classified our patients into 2 categories; those who received AST for non-SUP and those who received AST for SUP indications. Treatment with AST for non-SUP indications was considered appropriate, as supported by medical literature, if the patient had a specific indication or appropriate treatment purpose (e.g., GERD, PUD, dyspepsia, acute or suspected GI bleeding). SUP was defined as acid suppressing medication given to prevent stress ulcer bleeding in the absence of current evidence of bleeding. Appropriate administration of SUP was derived from an internal guideline that is based on the ASHP guidelines. Prophylaxis was considered appropriate if a patient had 1 absolute indication. Appropriate administration of SUP was derived from an internal guideline that is based on the ASHP guidelines. Prophylaxis was considered appropriate if a patient had 1 absolute indication [coagulopathy (defined as platelet count < 50,000 mm³) or an international normalization ratio of >1.5, or a partial thromboplastin time > 2 times the control value, or requiring mechanical ventilation for more than 48 h], or 2 or more relative indications (sepsis, occult bleeding, use of high dose corticosteroids (> 250 mg/d of hydrocortisone or the equivalent), recent use of NSAIDs for more than 3 mo, renal failure (end-stage renal disease or kidney transplantation), liver failure (cirrhosis or liver transplantation), enteral feeding and anti-coagulant use].

All patients were assessed for indications for AST, whether AST was received, the choice of AST, dosage, duration of treatment, route of administration and whether AST was continued after discharge.

RESULTS

One hundred and fifty-three patients were admitted during the study period and included in the analysis. The mean age was 59.8 ± 16.8 (mean ± SD) and 51% were females. Of the admitted patients, 130 (85%) were started on AST, out of which 11 (8.5%) were non-SUP indications and had a diagnosis that supports the use of this therapy (GI bleed, gastritis, esophagitis and GERD). 16 (12.3%) had an absolute indication for SUP, 59 (45.4%) had 2 or more relative indications for SUP and 44 (33.8%) received AST without an appropriate indication (Figure 1). In addition, one patient with an absolute indication for SUP and four with two or more relative indications did not receive AST. Ninety-two patients (70.8%) received AST by the oral route, while 38 patients (29.2%) received it intravenously. Rabeprazole was the most frequently used AST (59.2%), followed by omeprazole (24.6%), esomeprazole (11.6%) and ranitidine (4.6%). Of patients receiving AST for SUP, 95% were prescribed PPIs. The dose of AST was appropriate in 126 patients (96.9%) and the route of administration was appropriate in 123 patients (94.6%). Of the 130 AST medical orders, 129 (99.2%) were written by medical residents while only one was written by an attending physician. No adverse reactions were documented during the study period. The mean length of stay was 13.7 ± 11.0 d. Fifteen of the admitted patients (10%) were discharged on AST, 7 of which (47%) did not have an appropriate indication.

Figure 1 Use of acid suppressive therapy. AST: Acid suppressive therapy; SUP: Stress ulcer prophylaxis; GI: Gastrointestinal; GERD: Gastro-esophageal reflux disease.
DISCUSSION

There is a rapid increase in AST in hospitalized patients. In our study, a total of 85% of hospitalized non-critically ill patients received AST during the study period and this percentage is more than what has been reported by others (ranging between 27% and 71%)\(^ {1-7} \). Our study showed that AST use in non-critically ill patients is frequently inappropriate. Of the patients included in the study period, 33.8% received AST without an appropriate indication, 3.1% received wrong doses, 5.4% received intravenous AST while they were able to eat or take other oral medications, and almost half of the patients discharged on AST did not need it. The majority of prescriptions were made by medical residents.

Our results agree with previous reports on the overuse of AST in hospitalized patients. In a single day survey of hospitalized patients at 20 centers in Italy, Gullotta \textit{et al.}\(^ {8} \) found that 27% received AST, of which 51% was inappropriate. In addition, Nardino \textit{et al.}\(^ {9} \) reported the overuse of AST in a large community hospital in United States where 54% of hospitalized patients received AST, 65% of which were inappropriate. Pham \textit{et al.}\(^ {10} \) reported that only 10% of patients receiving AST in an internal medicine service were found to have an acceptable indication. Furthermore, Parente \textit{et al.}\(^ {11} \) reported that in hospitalized patients receiving AST, 68% of prescriptions were inappropriate, most of which were for SUP in low-risk patients. Finally, Hwang \textit{et al.}\(^ {12} \) reported that in non-critically ill patients in a teaching service 54.9% received AST, of which at least 58.5% was inappropriate. In our study, all the unnecessary AST use was attributed to the SUP indication. Although the indications for AST for the treatment of acid-related diseases and the prevention of gastric mucosal damage in an ICU setting has been well defined in the medical literature, in recent years the practice of SUP has become increasingly common in general medicine patients, with little to no evidence to support it. We assessed the appropriateness of SUP based on an internal guideline that is derived from the only published guidelines addressing SUP, the ASHP guidelines\(^ {8} \). Since the guidelines only endorse SUP for selected ICU patients, there is an urgent need for SUP guidelines for patients outside the ICU. Whether any non-ICU patients should receive SUP needs to be determined. Although the majority of unnecessary AST prescriptions were written by medical residents, it is unclear whether the decision to give SUP were made by the attending physicians or residents as many residents might have prescribed SUP at the request of the attending physicians.

The ASHP guidelines, published in 1999, do not include recommendations on the use of PPIs for SUP, yet they were the most frequently used agents in our study for that purpose (95%). This is consistent with recent reports showing that PPIs are more commonly being used for SUP despite limited data regarding their use for this indication\(^ {13} \). A recent meta-analysis comparing the safety and efficacy of PPIs vs H2RAs for SUP in critical care patients did not find strong evidence that PPIs were different from H2RAs in terms of stress-related upper GI bleeding prophylaxis, pneumonia and mortality\(^ {14} \). On the other hand, another meta-analysis concluded that in critically-ill patients, PPI use was associated with a significantly lower rate of clinically important bleeding than H2RAs with similar rates of nosocomial pneumonia\(^ {15} \). Based on available evidence, additional comparative studies with adequate patient numbers and pharmacoeconomic analyses are needed before PPIs can be considered the agents of choice for SUP in either ICU or non-ICU settings.

Although AST is often viewed as safe, it is associated with increased colonization of the upper GI tract with potentially pathogenic organisms, which was found to increase the risk of hospital-acquired pneumonia\(^ {16} \). In addition, gastric acid is an important defense against the acquisition of \textit{Clostridium difficile} spores and, by increasing gastric pH when using AST, the risk of \textit{Clostridium difficile} infection will increase\(^ {17-19} \). Furthermore, AST has the potential for drug-drug, drug-nutrient and drug-test interactions through a variety of mechanisms, as well as having agent-specific side effects\(^ {10} \). The practice of prescribing SUP in non-ICU hospitalized patients has substantial financial ramifications for both patients and hospitals. The cost of inappropriate SUP in non-ICU hospitalized patients was found in one trial to exceed $111,000 for one year\(^ {20} \).

Possible weaknesses of our study include the retrospective design and chart review. In addition, the study was conducted at a single center. Furthermore, it is difficult to fully extrapolate 2 mo data to a year as variation in prescribing habits may exist as medical residents acquire skills in the academic year cycle. Possible interventions to address unnecessary AST use include education of residents, junior medical staff and pharmacists, the use of ordering templates, and implementing internal guidelines for the appropriate AST use. Liberman \textit{et al.}\(^ {21} \) were able to reduce the rate of inappropriate SUP significantly by sparing one out of every 3 patients an inappropriate medication by conducting a low-cost educational intervention based on the principles of practice-based learning and improvement.

In our study, there was a high frequency of unnecessary use of AST in hospitalized non-critically ill patients with inappropriate continuation after discharge. Unnecessary AST can increase cost, drug interactions and adverse events. The results of our study highlight the need for interventions, including implementation of institutional protocols and prescriber education.

COMMENTS

\textbf{Background}

Acid suppressive therapy (AST), mainly proton pump inhibitors (PPIs) and histamine-2 receptor antagonists, is commonly prescribed for stress ulcer prophylaxis (SUP) for hospitalized non-critically ill patients without appropriate indication. Furthermore, it appears that once AST is started, medications are continued even after discharge, resulting in unnecessary increased drug cost and adverse events.

\textbf{Research frontiers}

Current evidence suggests that AST is commonly prescribed for SUP to hospitalized non-critically ill patients without appropriate indication. Furthermore,
it appears that once AST is started, medications are continued even after discharge, resulting in unnecessary increased drug cost and adverse events.

Applications
The high frequency of unnecessary use of AST in hospitalized non-critically ill patients with inappropriate continuation after discharge can increase cost, drug interactions and adverse events. There is a need for interventions, including implementation of institutional protocols and prescriber education.

Peer review
In this study, the authors reviewed medical records to assess whether or not prescribing AST to patients admitted to the general medical service in a tertiary care hospital in Beirut, Lebanon, from April 1 to May 31, 2011 was justified. The authors found that 33.8% of the patients in the study received acid suppressive treatment without an appropriate indication. The paper is well written and provides some useful information on the over use of PPIs in hospitalized patients.

REFERENCES

1. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-3122
2. Gullotta R, Ferraris L, Cortelezzi C, Minoli G, Prada A, Comin U, Rocca F, Ferrara A, Curzio M. Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drugs? Results of a multicentre study. Ital J Gastroenterol Hepatol 1997;29:325-329
3. Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006;40:1261-1266
4. Parente F, Cacino C, Gallus S, Baraggia S, Greco S, Pastore L, Bianchi Porro G. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther 2003;17:1503-1506
5. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol 2006;101:2200-2205
6. Martin-Echevarria E, Pereira Juliá A, Torralba M, Arriola Pereda G, Martín Dávila P, Mateos J, Rodríguez Zapata M. [Assessing the use of proton pump inhibitors in an internal medicine department]. Rev Esp Enferm Dig 2008;100:76-81
7. Hwang KO, Kolarov S, Cheng L, Griffith RA. Stress ulcer prophylaxis for non-critically ill patients on a teaching service. J Eval Clin Pract 2007;13:716-721
8. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999;56:347-379
9. Daley R, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med 2004;32:2008-2013
10. Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med 2010;38:1197-1205
11. Pongprasobchai S, Kridkratoke S, Nopmaneejumruslers C. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis. J Med Assoc Thai 2009;92:632-637
12. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301:2120-2128
13. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243-245
14. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhoea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-38
15. Louie TJ, Meddings J. Clostridium difficile infection in hospitals: risk factors and responses. CMAJ 2004;171:45-46
16. Liberman JD, Whelan CT. Brief report: Reducing inappropriate usage of stress ulcer prophylaxis among internal medicine residents. A practice-based educational intervention. J Gen Intern Med 2006;21:498-500

S-Editor Zhai HH L-Editor Roemmele A E-Editor Zheng XM